Xenikos B.V. announced the extension of its ongoing T-Guard Phase 1/2 study to Germany after approval from the Paul Ehrlich Institute on 31 July, 2015. T-Guard™ is Xenikos’ lead compound that is being developed for treatment of Graft versus Host Disease (GVHD), a frequent and potentially life-threatening complication of bone marrow and blood stem cell transplantation. The Phase 1/2 trial, which began in The Netherlands in March 2014, will be extended to the University Hospital of Muenster, in Germany.
Xenikos first evaluated the safety and efficacy of T-Guard in 2001 in a clinical pilot study at the Radboud University Medical Centre in Nijmegen, the Netherlands and is supported by SMB Life Sciences.
